Patents Assigned to Nodality, Inc.
-
Publication number: 20160267113Abstract: In one embodiment, one or more processor-readable media storing code representing instructions that when executed by one or more processors cause the one or more processors to receive a set of parameter values defining a boundary within a data space associated with a dataset. The dataset can represent signaling related to a test substance. A first metric can be defined based on a first portion of the dataset associated with a first region defined by the boundary. A second metric can be defined based on a second portion of the dataset associated with a second region defined by the boundary after the boundary is modified. The second region can be different than the first region.Type: ApplicationFiled: October 14, 2015Publication date: September 15, 2016Applicant: Nodality, Inc.Inventors: Steven C. BANVILLE, Santosh Krishna PUTTA, David C. SPELLMEYER, Nikil WALE, Erik EVENSEN, Norman Baylis PURVIS, JR., Gregory Daniel FRIEDLAND
-
Patent number: 9034257Abstract: The invention provides systems, compositions, kits and methods for automated processing of biological samples and analysis using a flow cytometer.Type: GrantFiled: October 27, 2009Date of Patent: May 19, 2015Assignee: Nodality, Inc.Inventors: Todd Covey, Adam Palazzo, Norman Purvis, James Cordiero, David Rosen
-
Publication number: 20150110736Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.Type: ApplicationFiled: June 3, 2014Publication date: April 23, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, Alessandra CESANO, Todd COVEY
-
Publication number: 20150017119Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: ApplicationFiled: May 16, 2014Publication date: January 15, 2015Applicant: Nodality, Inc.Inventors: Wendy J. FANTL, David B. ROSEN, Alessandra CESANO, Santosh K. PUTTA, Garry NOLAN, Aileen COHEN, Erik EVENSEN
-
Publication number: 20140255393Abstract: Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.Type: ApplicationFiled: February 28, 2014Publication date: September 11, 2014Applicant: Nodality, Inc.Inventors: Jason Ptacek, Rachael Hawtin, Erik Evensen, James Cordeiro, Alessandra Cesano
-
Patent number: 8778620Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: GrantFiled: May 17, 2012Date of Patent: July 15, 2014Assignee: Nodality, Inc.Inventors: Wendy J. Fantl, David B. Rosen, Alessandra Cesano, Santosh K. Putta, Garry Nolan, Aileen Cohen, Erik Evensen
-
Publication number: 20140170698Abstract: Fluorescently labeled microsphere calibration and quality control particles for use in establishing standardized fluorescence detector setup, monitoring daily QC of flow cytometers and quantitative calibration of the fluorescence detectors in traceable units of measure (molecules equivalent soluble fluorescence; MESF).Type: ApplicationFiled: August 29, 2013Publication date: June 19, 2014Applicant: Nodality, Inc.Inventor: Norman Baylis Purvis, JR.
-
Publication number: 20140147857Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: ApplicationFiled: October 9, 2013Publication date: May 29, 2014Applicant: Nodality, Inc.Inventors: Wendy J. Fantl, David B. Rosen, Alessandra Cesano, Santosh K. Putta, James R. Hackett, Michael Walker, Jing Shi
-
Publication number: 20140134650Abstract: The present invention provides an approach for the determination of the activation state of discrete cell populations and/or the state of one or more cellular networks in an individual, when modulated with a modulator that acts on one cell population to communicate with other cell populations in the network. The status of discrete cell populations and/or the state of one or more cellular networks can be correlated with the diagnosis, prognosis, choice or modification of treatment, and/or monitoring of a condition, and with screening of agents.Type: ApplicationFiled: November 6, 2013Publication date: May 15, 2014Applicant: Nodality, Inc.Inventors: Rachael Hawtin, Drew Hotson, Alessandro Cesano, Garry P. Nolan
-
Publication number: 20140127716Abstract: Provided herein are methods, compositions, and kits for determining cell signaling profiles in normal cells and comparing the cell signaling profiles of normal cells to cell signaling profiles from a test sample.Type: ApplicationFiled: November 5, 2013Publication date: May 8, 2014Applicant: Nodality, IncInventors: Diane Longo, Alessandra Cesano, Garry P. Nolan
-
Publication number: 20140093903Abstract: The invention provides methods, compositions, and systems for diagnosis, prognosis, evaluation of status, and/or determination of treatment for pathological conditions.Type: ApplicationFiled: August 27, 2013Publication date: April 3, 2014Applicant: Nodality, Inc.Inventors: Jason Ptacek, Racheal Hawtin, Erik Evensen
-
Publication number: 20140065633Abstract: An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds.Type: ApplicationFiled: June 7, 2013Publication date: March 6, 2014Applicant: Nodality, Inc.Inventors: Wendy J. Fantl, Alessandra Cesano, Todd Covey
-
Publication number: 20140057865Abstract: An embodiment of the present invention is a method for measuring activity of cell pathways, such as the cell cycle pathway and correlating the resulting profile to phenotypes. The resulting correlations are useful in diagnosis, prognosis, selection and development of drug treatment regimens, and drug screening applications.Type: ApplicationFiled: August 2, 2013Publication date: February 27, 2014Applicant: Nodality, Inc.Inventors: Wendy J. Fantl, Ying-Wen Huang
-
Publication number: 20140040265Abstract: The present invention relates to methods for representing multidimensional data. The methods of the present invention are well suited but not limited to the representation of multidimensional data in such a way as to enable the comparison and differentiation of data sets. For example, the invention may be applied to the representation of flow cytometric data. The invention further relates to a program storage device having instructions for controlling a computer system to perform the methods, and to a program storage device containing data structures used in the practice of the methods.Type: ApplicationFiled: August 29, 2013Publication date: February 6, 2014Applicant: Nodality, Inc.Inventors: Allan Robert Moser, Wade Thomas Rogers, Herbert Alan Holyst
-
Publication number: 20140017678Abstract: The present invention provides methods, compositions and kits for the characterization of cellular pathways in cells containing genetic alterations.Type: ApplicationFiled: March 13, 2013Publication date: January 16, 2014Applicant: Nodality, Inc.Inventor: Nodality Inc.
-
Publication number: 20130218474Abstract: Methods for determining a model that can characterize and distinguish normal cell from a diseased cell and methods for determining health or health-risk status of an individual based on a normal/health cell reference population of cells are described.Type: ApplicationFiled: January 25, 2013Publication date: August 22, 2013Applicant: Nodality, Inc.Inventor: Nodality, Inc.
-
Publication number: 20130173618Abstract: In one embodiment, one or more processor-readable media storing code representing instructions that when executed by one or more processors cause the one or more processors to receive a set of parameter values defining a boundary within a data space associated with a dataset. The dataset can represent signaling related to a test substance. A first metric can be defined based on a first portion of the dataset associated with a first region defined by the boundary. A second metric can be defined based on a second portion of the dataset associated with a second region defined by the boundary after the boundary is modified. The second region can be different than the first region.Type: ApplicationFiled: November 26, 2012Publication date: July 4, 2013Applicant: Nodality, Inc.Inventor: Nodality, Inc.
-
Publication number: 20130130279Abstract: The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.Type: ApplicationFiled: May 17, 2012Publication date: May 23, 2013Applicant: Nodality, Inc.Inventors: Wendy J. Fantl, David B. Rosen, Alessandra Cesano, Santosh K. Putta, Garry Nolan, Aileen Cohen, Erik Evensen
-
Publication number: 20130122524Abstract: This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens.Type: ApplicationFiled: November 8, 2012Publication date: May 16, 2013Applicant: Nodality, Inc.Inventor: Nodality, Inc.
-
Publication number: 20130123131Abstract: A method is disclosed in which control processes are used to maintain consistency across a research or diagnostic series of steps. Some embodiments of the processes include the use of fresh or lyophilized cell lines, beads, surface or other markers. The use of quality control processes is intended to monitor data from the underlying methods in order to detect unacceptable variations and to allow for exclusion or normalization. Overlapping control processes allows for tighter control and for redundancy in the monitoring.Type: ApplicationFiled: November 9, 2012Publication date: May 16, 2013Applicant: Nodality, Inc.Inventor: Nodality, Inc.